# Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction

> **NCT00080002** · PHASE2 · TERMINATED · sponsor: **Enzon Pharmaceuticals, Inc.**

## Conditions studied

- Cancer of Stomach
- Gastroesophageal Cancer

## Interventions

- **DRUG:** Pegamotecan

## Key facts

- **NCT ID:** NCT00080002
- **Lead sponsor:** Enzon Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-12
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2012-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00080002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00080002, "Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00080002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*